Overview

Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody

Status:
Unknown status

Trial end date:
2021-07-08

Target enrollment:

Participant gender:

Summary

The main objective was to evaluate the safety and efficacy of anlotinib hydrochloride combined with pd-1 antibody second-line and above in the treatment of advanced solid tumors

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Henan Cancer Hospital

Collaborator:

Cttq

Treatments:

Antibodies
Immunoglobulins